Background and objectives: The role of CCR2-V64I polymorphism in various cancers has been reported in many studies. However, results from published studies on the association between CCR2-V64I polymorphism and cancer risk are conflicting. Therefore, we performed a meta-analysis to estimate the overall cancer risk associated with the polymorphism. Methods: Electronic searches of PubMed and EMBASE were conducted for all publications on the association between this variant and cancer. Odds ratios (OR) with 95% confidence intervals (95% CI) were used to access the strength of this association. Results: Sixteen studies with 2661 cancer patients and 5801 healthy controls were included. Overall, significant association was found between the CCR2-V64I polymorphism and cancer risk (OR = 1.84,95% CI = 1.35-2.51, AA vs GA/GG, P = 037). In the subgroup analysis stratified by cancer types, there was a significant association between this polymorphism and bladder cancer (OR = 2.06,95% CI = 1.02-4.15, AA vs GA/GG, P = 0.11), cervical cancer (OR = 3.34, 95% CI = 1A8-7.50, AA vs GG, P = 0.56), and oral cancer (OR = 2.04, 95% CI = 1.462.84, GA vs GG, P = 0.70). In the subgroup analysis stratified by ethnicities, an increased cancer risk was also found in Europeans (OR = 231, 95% CI = 1.45-3.68, AA vs GA/GG, P = 0.16) and Asians (OR = 1.88, 95% CI = 1.12-3.16, AA vs GA/GG, P = 0.92). Conclusion: This meta-analysis suggested that CCR2-V641 polymorphism may contribute to an increased risk of cancer. 0 2013 Elsevier B.V. All rights reserved.